CRMD Stock Overview
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
CorMedix Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.24 |
| 52 Week High | US$7.00 |
| 52 Week Low | US$2.57 |
| Beta | 1.6 |
| 11 Month Change | 36.24% |
| 3 Month Change | 18.41% |
| 1 Year Change | 51.09% |
| 33 Year Change | -3.41% |
| 5 Year Change | -24.73% |
| Change since IPO | -58.40% |
Recent News & Updates
Recent updates
We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth
Apr 06
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely
Nov 02Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation
Jul 31CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans
Feb 25FDA again rejects CorMedix's application for lead candidate DefenCath, shares sink ~60%
Aug 08Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation
Jul 16We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely
Mar 01Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation
Sep 09CorMedix Inc.'s (NASDAQ:CRMD) Intrinsic Value Is Potentially 58% Above Its Share Price
Feb 11We're Hopeful That CorMedix (NYSEMKT:CRMD) Will Use Its Cash Wisely
Jan 04Shareholder Returns
| CRMD | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 10.4% | 1.1% | 0.06% |
| 1Y | 51.1% | 20.0% | 22.6% |
Return vs Industry: CRMD exceeded the US Pharmaceuticals industry which returned 19.3% over the past year.
Return vs Market: CRMD exceeded the US Market which returned 22.2% over the past year.
Price Volatility
| CRMD volatility | |
|---|---|
| CRMD Average Weekly Movement | 11.5% |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CRMD's share price has been volatile over the past 3 months.
Volatility Over Time: CRMD's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 83 | Joe Todisco | www.cormedix.com |
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.
CorMedix Inc. Fundamentals Summary
| CRMD fundamental statistics | |
|---|---|
| Market cap | US$339.07m |
| Earnings (TTM) | -US$53.12m |
| Revenue (TTM) | US$806.12k |
432.4x
P/S Ratio-6.6x
P/E RatioIs CRMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRMD income statement (TTM) | |
|---|---|
| Revenue | US$806.12k |
| Cost of Revenue | US$1.33m |
| Gross Profit | -US$522.26k |
| Other Expenses | US$52.59m |
| Earnings | -US$53.12m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.95 |
| Gross Margin | -64.79% |
| Net Profit Margin | -6,589.10% |
| Debt/Equity Ratio | 0% |
How did CRMD perform over the long term?
See historical performance and comparison